Skip to main content
. 2025 Aug 22;25:1060. doi: 10.1186/s12879-025-11389-1

Table 1.

Characteristics of the study population according to malaria severity

Characteristic Total
(N = 289)
Non-severe malaria (N = 169) Severe malaria (N = 120) p-value Crude
OR (95%CI)
Age (years); mean, SD 40.6 ± 19.3 38.0 ± 17.6 44.2 ± 21.2 0.007
Age (categorised)
 20–29 124 (42.9) 77 (45.5) 47 (39.2)
 30–39 48 (16.6) 30 (17.8) 18 (15.0) 0.962 1.02 (0.51–2.03)
 40–49 24 (8.3) 18 (10.7) 6 (5.0) 0.282 0.58 (0.22–1.57)
 50–59 24 (8.3) 17 (10.1) 7 (5.8) 0.496 0.72 (0.27–1.87)
 ≥ 60 69 (23.9) 27 (16.0) 42 (35.0) 0.002 2.55 (1.39–4.66)
Sex
 Male 107 (37.0) 69 (40.8) 38 (31.7)
 Female 182 (63.0) 100 (59.2) 82 (68.3) 0.089 1.53 (0.94–2.51)
Education
 None 17 (5.9) 4 (2.4) 13 (10.8)
 Primary 63 (21.8) 32 (18.9) 31 (25.8) 0.060 0.31 (0.09–1.05)
 Secondary 42 (14.5) 19 (11.2) 23 (19.2) 0.153 0.39 (0.11–1.41)
 High school 43 (14.8) 24 (14.2) 19 (15.8) 0.035 0.25 (0.07–0.91)
 Higher education 124 (42.9) 90 (54.2) 34 (28.3) 0.000 0.12 (0.04–0.38)
Occupation
 Student 86 (29.8) 60 (35.5) 26 (21.7)
 Health worker 20 (6.9) 16 (9.5) 4 (3.3) 0.426 0.62 (0.19–2.03)
 Farming 69 (23.9) 34 (20.1) 35 (29.2) 0.008 2.45 (1.26–4.74)
 Business 67 (23.2) 32 (18.9) 35 (29.2) 0.005 2.61 (1.34–5.08)
 Others 47 (16.2) 27 (16.0) 20 (16.6) 0.155 1.71 (0.81–3.57)
Comorbidities reported by patients or recorded in medical files
 Diabetes 15 (5.2) 4 (2.4) 11 (9.2) 0.016 4.23 (1.31–13.7)
 Hypertension 30 (10.4) 17 (10.1) 12 (10.0) 0.255 1.35 (0.80–2.28)
 Liver disease1 4 (1.4) 3 (1.8) 1 (0.8) 0.912 1.06 (0.40–2.77)
 Asthma 2 (0.7) 2 (1.2) 0
 Cardiac disease2 4 (1.4) 3 (1.8) 1 (0.8) 0.350 1.78 (0.53–5.93)
 Cancer3 4 (1.4) 0 4 (3.3) 0.581 1.21 (0.62–2.35)
 Positive HIV test at inclusion4 10 (3.6) 5 (3.1) 5 (4.4) 0.568 1.45 (0.41–5.11)
 Pregnancy 32 (17.6) 21 (21.0) 11 (13.4) 0.641 0.87 (0.49–1.54)
Hemoglobin traits
 Sickle-cell traits
  AA 243 (84.1) 142 (84.0) 101 (84.2)
  AS 27 (9.3) 18 (10.7) 9 (7.5) 0.383 0.69 (0.30–1.59)
  SS 3 (1.1) 1 (0.6) 2 (1.7) 0.411 2.75 (0.25–30)
  Missing 16 (5.5) 8 (4.7) 8 (6.6)
Blood group5
 A 68 (22.8) 41 (24.3) 26 (21.7)
 B 56 (19.4) 36 (21.3) 19 (14.7) 0.631 0.72 (0.03–8.45)
 AB 13 (4.5) 6 (3.6) 7 (5.8) 1.00 1.53 (0.05–19)
 O 129 (44.6) 73 (43.2) 56 (46.7) 0.866 0.78 (0.05–12)
 Missing 23 (7.9) 11 (6.5) 12 (10.0)
Health behavioural factors
 Patient delay in consultation, days from symptom onset
  0–1 36 (13.6) 21 (12.6) 15 (12.5)
  2–3 113 (42.6) 67 (40.4) 46 (38.3) 0.919 0.96 (0.45–2.06)
  ≥ 4 116 (43.7) 67 (39.6) 49 (40.8) 0.889 1.06 (0.49–2.25)
  Missing 24 (8.3) 14 (8.3) 10 (8.3)
Malaria home treatment 82 (28.4) 49 (29.0) 33 (27.5) 0.742 0.92 (0.54–1.54)
Missing 1 (0.3) 1 (0.8)

Legend: Data is presented as numbers and percentages (%) if not otherwise stated.

SD = Standard deviation

1cholecystitis, chronic hepatitis B and hepatitis C, steatohepatitis

2 heart failure, left ventricular hypertrophy, and cardiomyopathy

3uterus, breast, multiple myeloma, prostate; 4Nine out of these 10 cases were previously known; 5A + = 66, A- = 1, A (unconfirmed Rhesus) = 1, B + = 55, B- = 1, AB + = 12, AB- = 1, O + = 127, O- = 2